Frank Berthold

University of Cologne — Germany

Medicine · Health Sciences

75h-index26.8kcitations506works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(343), Cancer, Hypoxia, and Metabolism(110), Cancer therapeutics and mechanisms(69), Lung Cancer Research Studies(38), Glioma Diagnosis and Treatment(35)

Publications505 total

Minimal Residual Disease Detection in Peripheral Blood of Patients With High-Risk Neuroblastoma Correlates With Outcome in the International GPOH-DCOG Prospective Validation Study
JCO Precision Oncology·2025Open Access
International neuroblastoma risk group consortium: a model of networking for rare cancers
JNCI Journal of the National Cancer Institute·2025· 2 citedOpen Access
Sensitive liquid biopsy monitoring correlates with outcome in the prospective international GPOH-DCOG high-risk neuroblastoma RT-qPCR validation study
Journal of Experimental & Clinical Cancer Research·2024· 3 citedOpen Access
Noncompliance of pediatric cancer patients with chemotherapy: A single-center experience in a lower-middle income country
Pediatric Hematology and Oncology·2023· 5 cited
Comparing presentations and outcomes of children with cancer: a study between a lower-middle-income country and a high-income country
BMC Pediatrics·2023· 24 citedOpen Access
Supplementary material for "The asymmetric adrenals: Sexual dimorphism of adrenal tumours"
Zenodo (CERN European Organization for Nuclear Research)·2023Open Access
Asymmetric Adrenals: Sexual Dimorphism of Adrenal Tumors
The Journal of Clinical Endocrinology & Metabolism·2023· 18 citedOpen Access
Image‐defined risk factors in localized thoracic neuroblastoma and ganglioneuroma
Pediatric Blood & Cancer·2023· 2 citedOpen Access
Supplementary Data 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Supplementary Table 6A from High <i>ALK</i> Receptor Tyrosine Kinase Expression Supersedes <i>ALK</i> Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
2023Open Access
Data from Differential Expression of Neuronal Genes Defines Subtypes of Disseminated Neuroblastoma with Favorable and Unfavorable Outcome
2023Open Access
Supplementary Table 6C from High <i>ALK</i> Receptor Tyrosine Kinase Expression Supersedes <i>ALK</i> Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
2023Open Access
Supplementary Table 4 from High <i>ALK</i> Receptor Tyrosine Kinase Expression Supersedes <i>ALK</i> Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
2023Open Access
Supplementary Data from Subclassification and Individual Survival Time Prediction from Gene Expression Data of Neuroblastoma Patients by Using CASPAR
2023Open Access
Supplementary Table 5B from High <i>ALK</i> Receptor Tyrosine Kinase Expression Supersedes <i>ALK</i> Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
2023Open Access
Supplementary Table 3 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Supplementary Table 6B from High <i>ALK</i> Receptor Tyrosine Kinase Expression Supersedes <i>ALK</i> Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
2023Open Access
Supplementary Table 1 from Differential Expression of Neuronal Genes Defines Subtypes of Disseminated Neuroblastoma with Favorable and Unfavorable Outcome
2023Open Access
Legends to Supplementaries from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
Supplementary Data 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
2023Open Access
page 1 of 26Next →

Frequent Co-authors

Barbara Hero(20), Matthias Fischer(9), Thorsten Simon(9), Frank Westermann(8), André Oberthuer(7), Martin Schrappe(7), Manfred Schwab(6), Katherine K. Matthay(6), Wendy B. London(6), Jessica Theißen(6), Peter F. Ambros(5), Andrew D.J. Pearson(5), Susan L. Cohn(5), Benedikt Brors(5), Yvonne Kahlert(5), Robert C. Seeger(4), Frederik Roels(4), Günter Henze(4), Torsten Pietsch(4), Karen Ernestus(4)